Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $638 million versus the consensus estimate of $627.35 million.

GUIDANCE:

Exact Sciences sees FY2024 revenue of $2.81-2.85 billion, versus the consensus of $2.833 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.